Dendreon Crosses Fingers, Knocks on Wood, And Resubmits Provenge to FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
The Seattle prostate-cancer vaccine maker has filed again for approval two and a half years after the agency's contentious rejection.
You may also be interested in...
No Drama Dendreon: Anticipated Provenge Launch Appears On Track
The biotech says it will launch prostate cancer vaccine the day after approval.
No Drama Dendreon: Anticipated Provenge Launch Appears On Track
The biotech says it will launch prostate cancer vaccine the day after approval.
Dendreon Raises $230 Million To Fund Filing And Anticipated Launch Of Provenge
With strong overall survival data in hand for its prostate cancer vaccine, Seattle biotech takes advantage of increased investor interest.